CD274 and breast carcinoma: found that deglycosylation of PD‐L1 in breast cancer samples significantly enhanced the binding affinity and signaling strength of anti–PD‐L1 antibodies, thereby facilitating the reactivation of T cell immunity by blocking PD‐1/PD‐L1 interactions.[17] These findings indicate that the glycosylation status of PD‐L1 is closely associated with its immunomodulatory function.